Cabozantinib and temozolomide in patients with unresectable or metastatic leiomyosarcoma and other soft tissue sarcomas: a multicentre, single-arm, lead-in phase 2 trial
Authors:
- 16 January 2026
- journal article
- Published by Elsevier in The Lancet Oncology
- Vol. 27 (2) , 223-232
Abstract
No abstract availableKeywords
Funding Information
- Exelixis
This publication has 26 references indexed in Scilit:
- Efficacy of Pazopanib With or Without Gemcitabine in Patients With Anthracycline- and/or Ifosfamide-Refractory Soft Tissue SarcomaJAMA Oncology, 2021
- A phase II of gemcitabine combined with pazopanib followed by pazopanib maintenance, as second-line treatment in patients with advanced leiomyosarcomas: A unicancer French Sarcoma Group study (LMS03 study)European Journal of Cancer, 2020
- Overall survival and histology‐specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcomaCancer, 2019
- Cabozantinib: A Multitargeted Oral Tyrosine Kinase InhibitorPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2018
- Gemcitabine-based chemotherapy in sarcomas: A systematic review of published trialsCritical Reviews in Oncology/Hematology, 2016
- Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high‐grade gliomasCancer, 2015
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- A phase II trial of temozolomide as a 6‐week, continuous, oral schedule in patients with advanced soft tissue sarcomaCancer, 2005
- A phase II trial of temozolomide in patients with unresectable or metastatic soft tissue sarcomaCancer, 2003
- Impact of c-Met expression on angiogenesis in soft tissue sarcomas: correlation to microvessel-densityJournal of Cancer Research and Clinical Oncology, 2003